PY2117315A - Compuestos para uso en el tratamiento de la infección por coronavirus - Google Patents

Compuestos para uso en el tratamiento de la infección por coronavirus

Info

Publication number
PY2117315A
PY2117315A PY202102117315A PY2117315A PY2117315A PY 2117315 A PY2117315 A PY 2117315A PY 202102117315 A PY202102117315 A PY 202102117315A PY 2117315 A PY2117315 A PY 2117315A PY 2117315 A PY2117315 A PY 2117315A
Authority
PY
Paraguay
Prior art keywords
treatment
compounds
coronavirus infection
sub
strong
Prior art date
Application number
PY202102117315A
Other languages
English (en)
Spanish (es)
Inventor
Losada González Alejandro
María Fernández-sousa José
Avilés Marín Pablo
Fudio Muñoz Salvador
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PY2117315A publication Critical patent/PY2117315A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PY202102117315A 2020-03-02 2021-03-02 Compuestos para uso en el tratamiento de la infección por coronavirus PY2117315A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16

Publications (1)

Publication Number Publication Date
PY2117315A true PY2117315A (es) 2022-05-10

Family

ID=74797953

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202102117315A PY2117315A (es) 2020-03-02 2021-03-02 Compuestos para uso en el tratamiento de la infección por coronavirus

Country Status (17)

Country Link
US (1) US20230158102A1 (https=)
EP (1) EP4114436A1 (https=)
JP (1) JP2023517295A (https=)
KR (1) KR20220151181A (https=)
CN (1) CN115666615A (https=)
AU (1) AU2021232534A1 (https=)
BR (1) BR112022017008A2 (https=)
CA (1) CA3169791A1 (https=)
CL (1) CL2022002398A1 (https=)
CO (1) CO2022014115A2 (https=)
IL (1) IL296066A (https=)
MX (1) MX2022010922A (https=)
PE (1) PE20231069A1 (https=)
PY (1) PY2117315A (https=)
TW (1) TW202144380A (https=)
UY (1) UY39108A (https=)
WO (1) WO2021175826A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021231521A1 (en) * 2020-03-02 2022-10-06 Pharma Mar, S.A. PLD for use in combination in the treatment of coronavirus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー,マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US7605135B2 (en) * 2003-11-10 2009-10-20 The University Of Hong Kong Baicalin as a treatment for SARS infection
JP2012512839A (ja) * 2008-12-19 2012-06-07 ファルマ、マール、ソシエダード、アノニマ 抗腫瘍性化合物
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
CN115461067A (zh) * 2020-03-02 2022-12-09 法马马有限公司 用于炎症的化合物

Also Published As

Publication number Publication date
KR20220151181A (ko) 2022-11-14
UY39108A (es) 2021-09-30
JP2023517295A (ja) 2023-04-25
CN115666615A (zh) 2023-01-31
MX2022010922A (es) 2022-09-29
PE20231069A1 (es) 2023-07-17
AU2021232534A1 (en) 2022-10-06
TW202144380A (zh) 2021-12-01
US20230158102A1 (en) 2023-05-25
BR112022017008A2 (pt) 2022-10-11
CO2022014115A2 (es) 2022-11-18
IL296066A (en) 2022-11-01
CL2022002398A1 (es) 2023-06-30
EP4114436A1 (en) 2023-01-11
CA3169791A1 (en) 2021-09-10
WO2021175826A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
LT3953330T (lt) Nitrilo turintys junginiai, naudingi kaip antivirusiniai agentai, skirti koronavirusinei infekcijai gydyti
HRP20050516B1 (hr) N-alkil-4-metilenamino-3-hidroksi-2-piridoni kao antimikrobni lijekovi
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
BRPI0906525A2 (pt) substâncias policrômicas e seu uso
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
EA200601896A1 (ru) Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
CY1112200T1 (el) Συνδυασμοι για τη θεραπεια ασθενειων που ενεχουν κυτταρικο πολλαπλασιασμο
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
CY1109497T1 (el) Παραγωγα θειοφενιου ως αντιβιοτικοι παραγοντες για λοιμωξη/μολυνση φλαβοϊου (flavivirus)
EA200970572A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
CY1110137T1 (el) Συμπυκνωμενες τρικυκλικες ενωσεις peri χρησιμες ως αντιβακτηριακοι παραγοντες
MX2025015186A (es) Inhibidores de pi3k y uso de estos
MX392601B (es) Análogos sintéticos de las ecteinascidinas y su uso como agentes antitumorales.
BRPI0514372A (pt) inibidores de tiazol de frutose 1, 6-bisfosfatase
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
AR047248A1 (es) Combinacion activa como biocida para aplicaciones agricolas
ATE541461T1 (de) Synergistische wirkstoffkombinationen
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS